Ran Nussbaum built his reputation less on picking trends and more on staying deeply involved in the companies he backs, a style shaped by his early career at Israel's largest business-intelligence and strategic consulting firm rather than the usual banking or operating path; he was also talking early and specifically about CAR-T, TCR, checkpoint biology, CRISPR, and personalized medicine, helped build new companies off Roche's wish list to bridge Israeli science into global biotech, and has been closely tied to Kite Pharma as a founding board member through its acquisition by Gilead. Alongside chairman roles at companies like Keros and OCON, he has long been described as one of the two people actually running Pontifax day to day, alongside Tomer Kariv.